89,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
  • Gebundenes Buch

Advances in Cancer Research, Volume 144, the latest release in this ongoing, well-regarded serial, provides invaluable information on the exciting and fast-moving field of cancer research. Chapters in this new release include Gene-Environment-Microenvironment Interactions in Melanomagenesis, PP2A and the Cell Cycle, Current Progress Defining Calcium Signals as Therapeutic Targets in Cancer Cells, and much more.

Produktbeschreibung
Advances in Cancer Research, Volume 144, the latest release in this ongoing, well-regarded serial, provides invaluable information on the exciting and fast-moving field of cancer research. Chapters in this new release include Gene-Environment-Microenvironment Interactions in Melanomagenesis, PP2A and the Cell Cycle, Current Progress Defining Calcium Signals as Therapeutic Targets in Cancer Cells, and much more.
Autorenporträt
Professor & Chairman, Dept of Cell & Molecular Pharmacology John C. West Chair of Cancer Research, Medical University of South Carolina, USA
The Tew laboratory maintains an interest in using redox pathways as a platform to develop therapeutic strategies through drug discovery/development and biomarker identification. We interrogate how reactive oxygen and nitrogen species (ROS/RNS) impact cancer cells and develop novel drugs that impact on glutathione based pathways. Our research efforts have been integral to studies that have identified glutathione S-transferases (GST) as important in drug resistance, catalytic detoxification and as arbiters of kinase-mediated cell signaling events. In addition, we have been instrumental in defining how GSTP contributes to the process by which cells respond to ROS by selective addition of glutathione to specific protein clusters, so called S-glutathionylation. Each of these research areas has had broad impact on a number of cancer disciplines. Moreover, we have also been seminally involved in the Phase I to III clinical testing of three oncology drugs, Telcyta, Telintra and NOV-002. Other ongoing translational efforts have produced two ongoing clinical trials to measure the effectiveness of serum S-glutathionylated serine proteinase inhibitors as possible biomarkers for exposure to hydrogen peroxide mouthwashes and radiation.